CO5300464A1 - Metodo para regular la angiogenesis utilizando proteina ryk - Google Patents

Metodo para regular la angiogenesis utilizando proteina ryk

Info

Publication number
CO5300464A1
CO5300464A1 CO01036462A CO01036462A CO5300464A1 CO 5300464 A1 CO5300464 A1 CO 5300464A1 CO 01036462 A CO01036462 A CO 01036462A CO 01036462 A CO01036462 A CO 01036462A CO 5300464 A1 CO5300464 A1 CO 5300464A1
Authority
CO
Colombia
Prior art keywords
sec
protein
ryk
variant
site
Prior art date
Application number
CO01036462A
Other languages
English (en)
Spanish (es)
Inventor
Steve Roczniak
A Dubois-Strin Nathalie
Alya Zolotorev
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CO5300464A1 publication Critical patent/CO5300464A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO01036462A 2000-05-10 2001-05-09 Metodo para regular la angiogenesis utilizando proteina ryk CO5300464A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56878300A 2000-05-10 2000-05-10

Publications (1)

Publication Number Publication Date
CO5300464A1 true CO5300464A1 (es) 2003-07-31

Family

ID=24272718

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01036462A CO5300464A1 (es) 2000-05-10 2001-05-09 Metodo para regular la angiogenesis utilizando proteina ryk

Country Status (13)

Country Link
EP (1) EP1287121A2 (enExample)
JP (1) JP2004527206A (enExample)
AR (1) AR028424A1 (enExample)
AU (1) AU2001261343A1 (enExample)
CA (1) CA2408349A1 (enExample)
CO (1) CO5300464A1 (enExample)
DO (1) DOP2001000164A (enExample)
EC (1) ECSP014068A (enExample)
GT (1) GT200100079A (enExample)
PE (1) PE20011218A1 (enExample)
SV (1) SV2002000442A (enExample)
UY (1) UY26696A1 (enExample)
WO (1) WO2001085789A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005516608A (ja) * 2002-02-06 2005-06-09 デヴェロゲン アクチエンゲゼルシャフト フュア エントヴィックルングスビオローギッシェ フォルシュング エネルギー恒常性の調節に関与するキナーゼ
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
ES2732925T3 (es) 2014-07-18 2019-11-26 Sanofi Sa Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer
EP4387669A4 (en) * 2021-08-18 2025-06-25 The Regents Of The University Of California Anti-related-to-receptor tyrosine kinase (RRYK) antibodies and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023429A1 (en) * 1992-05-11 1993-11-25 Ludwig Institute For Cancer Research Receptor-type tyrosine kinase-like molecules
AU4606196A (en) * 1994-12-23 1996-07-19 Ludwig Institute For Cancer Research Assay, receptor proteins and ligands
AU4278299A (en) * 1998-06-11 1999-12-30 Astrazeneca Ab Human receptor tyrosine kinase
ES2316194T3 (es) * 1998-10-28 2009-04-01 Cornell Research Foundation, Inc. Metodos para la regulacion de la angiogenesis y la integridad vascular utilizando los ligandos bdnf, nt-3 y nt-4.

Also Published As

Publication number Publication date
AU2001261343A1 (en) 2001-11-20
ECSP014068A (es) 2002-02-25
JP2004527206A (ja) 2004-09-09
DOP2001000164A (es) 2002-05-15
SV2002000442A (es) 2002-07-03
WO2001085789A2 (en) 2001-11-15
UY26696A1 (es) 2001-12-28
PE20011218A1 (es) 2002-02-01
CA2408349A1 (en) 2001-11-15
GT200100079A (es) 2001-12-31
WO2001085789A3 (en) 2002-05-16
AR028424A1 (es) 2003-05-07
EP1287121A2 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
AR021448A1 (es) Metodo para producir un polipeptido quimerico
AR012531A1 (es) Composicion para cuidado personal, composicion para repasador y metodo para minimizar o reducir la comezon o quemado de la piel a causa de composicionespara cuidado personal que contienen acido.
ES2183945T3 (es) Composiciones para mejorar el aporte de un agente por electrotransporte.
PE20110236A1 (es) Proteccion y mejoramiento de celulas, tejidos y organos que responden a la eritropoyetina
BR9814276A (pt) Antìgenos de superfìcie
BR9609393A (pt) Composição injetável de colágeno; segmentos de fibra de colágeno reconstituìdos.
ATE240729T1 (de) Methoden und zusammensetzungen zur lipidisierung hydrophiler moleküle
NO992068D0 (no) Mikroemulsjon og fremgangsmÕte for fremstilling av denne
ATE208612T1 (de) Biologisch erodierbare vorrichtung zur verabreichung von wirkstoffen
ES2146552B1 (es) Peptidos inhibidores de tgf/31
ES2123910T3 (es) Composiciones que contienen sales anfoteras de alfa-hidroxiacidos y monocaprilato de glicerol.
BR0108734A (pt) Composições antimicrobiais ácidas para tratar alimento e superfìcies de contato do alimento e métodos para uso das mesmas
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
CA2480226A1 (en) Stable pharmaceutical composition containing factor viii
NO20073914L (no) Biologisk aktive peptider
BRPI0514411A (pt) formulação, e, método de produzir uma formulação
PE20070999A1 (es) Emulsion de acido graso esencial intravenosa
CO5570658A2 (es) Composicion y metodo para el tratamiento de la diabetes
MA26625A1 (fr) Conjugue de proteine hedgehog a activite accrue, procede pour sa production, et son utilisation therapeutique
CO5300464A1 (es) Metodo para regular la angiogenesis utilizando proteina ryk
ATE245433T1 (de) Verwendung von lipopeptiden oder lipoproteinen zur wundbehandlung
PT1095141E (pt) Metodo para a producao de um peptido com um pi acima de 8 ou abaixo de 5
ES2144734T3 (es) Procedimiento para la obtencion de concentrados acuosos de tensioactivos.
CO5280064A1 (es) Proteina que tiene actividada como modulador de agiogenesis